Get started
Author

Josef A. Gramespacher

Observed names: Gramespacher, Josef, Josef Gramespacher
ORCID: 0000-0003-3478-0183
Observed ORCID: 0000-0003-3478-0183
OpenAlex ID: A5006298755
Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
2021 · Adam D. Cotton, Duy P. Nguyen, et al. · Journal of the American Chemical Society · 550
PDF
Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins
2022 · Katarina Pance, Josef A. Gramespacher, et al. · Nature Biotechnology · 268
PDF
Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins
2022 · Josef A. Gramespacher, Adam D. Cotton, et al. · ACS Chemical Biology · 106
Intein Zymogens: Conditional Assembly and Splicing of Split Inteins via Targeted Proteolysis
2017 · Josef A. Gramespacher, Adam J. Stevens, et al. · Journal of the American Chemical Society · 61
PDF
Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity
2020 · Irene Lui, Xin X. Zhou, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 34
PDF
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2
2021 · Shion A. Lim, Josef A. Gramespacher, et al. · mAbs · 33
Proximity Induced Splicing Utilizing Caged Split Inteins
2019 · Josef A. Gramespacher, Antony J. Burton, et al. · Journal of the American Chemical Society · 27
An Atypical Mechanism of Split Intein Molecular Recognition and Folding
2018 · Adam J. Stevens, Giridhar Sekar, et al. · Journal of the American Chemical Society · 25
Improved protein splicing using embedded split inteins
2017 · Josef A. Gramespacher, Adam J. Stevens, et al. · Protein Science · 23
PDF
Abstract 1866: Discovery of mutation-independent EGFR degrading bispecific antibodies that suppress tumor growth in preclinical tumor models
2024 · Jonathan Sitrin, Lisa Marshall, et al. · Cancer Research · 2
Abstract 1725: Dual modality of EpiTAC bispecific degrader ADCs combines c-MET degradation with cytotoxic payload delivery to overcome limitations of current c-MET-targeted therapies
2026 · Lisa Marshall, Jonathan Sitrin, et al. · Cancer Research · 1
Abstract ND04: EPI-326: A novel mutation-independent and normal tissue-sparing EGFR bispecific antibody that degrades EGFR for the treatment of EGFR-driven solid tumors
2026 · Jonathan Sitrin, Lisa Marshall, et al. · Cancer Research
Abstract 4411: Discovery of mutation-independent cKit degrading bispecific antibodies that suppress tumor growth in preclinical models of GIST
2026 · Kenneth Ng, Shruti Yadav, et al. · Cancer Research
Verbundprojekt: "AI-assisted Technology Transfer"; Akronym: AITT
2025 · Schiller, Bernd, Coerdt, Roland, et al. · RENATE
AIBetOn3D: KI-assistierter 3D-Druck für Baustoffe
2025 · Greif, Lucas, Kimmig, Andreas, et al. · RENATE
Abstract 1571: Discovery of c-MET degrading bispecific antibodies (EpiTACs) for NSCLC and other c-MET driven tumors
2025 · Jonathan Sitrin, Hai Tran, et al. · Cancer Research
Design and Application of Conditionally Activated Split Inteins
2019 · Josef A. Gramespacher
Works count: 17
Citation count: 1,130
H-index: 9
I10-index: 9
Year
Topic
Type